VSVaka Kristin Sigurjonsdottir

Vaka Kristin Sigurjonsdottir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vaka Kristin Sigurjonsdottir has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Lynn Maestretti

    Pediatric Kidney Transplant Program, Division of Nephrology, Department of Pediatrics, Lucile Packard Children’s Hospital Stanford, Palo Alto, California

    3 shared publications
  • Abanti Chaudhuri

    Division of Nephrology, Department of Pediatrics, Stanford University, Palo Alto, California

    2 shared publications
  • Amy Gallo

    Division of Abdominal Transplantation, Department of Surgery, Stanford University, Palo Alto, California

    2 shared publications
  • Anne McGrath

    Pediatric Kidney Transplant Program, Division of Nephrology, Department of Pediatrics, Lucile Packard Children’s Hospital Stanford, Palo Alto, California

    2 shared publications
  • Paul C. Grimm

    Pediatric Nephrology, Stanford University Children’s Health, Stanford University School of Medicine, Palo Alto, USA

    2 shared publications
  • Runolfur Palsson

    Division of Nephrology, Internal Medicine and Emergency Services, Landspitali–The National University Hospital of Iceland, Reykjavik, Iceland

    2 shared publications

Latest Publications

  • Open Access

    Donor-derived cell-free DNA testing in pediatric kidney transplant recipients: indications and clinical utility

    by Jayanthi Chandar, Vaka Sigurjonsdottir, Marissa Defreitas, Tara Gavcovich, Mingming Zhou, Renata Glehn-Ponsirenas, George Burke

    Background: We describe our single-center experience in performing donor-derived cell-free DNA (dd-cfDNA) testing for a clinical indication in pediatric kidney transplant recipients. Methods: Dd-cfDNA was done for increase in creatinine, appearance of de novo anti-HLA antibodies (dnHLAab) and for a clinical indication. We compared clinical characteristics of patients with dd-cfDNA > 1 with those with dd-cfDNA ≤ 1 and also compared dd-cfDNA in patients with no biopsy proven rejection (BPAR) or dnHLAab with those with BPAR, and those with dnHLAab and no BPAR. Results: Chart review was performed in 106 patients with a mean age of 11.0 ± 5.5 years. When compared with 62 patients with dd-cfDNA ≤ 1, 59.0% (26/44) of patients with dd-cfDNA > 1 had BPAR (OR 13.5: 95%CI 4.6,38; p < 0.0001), and 88.1% (37/44) had dnHLAab (OR 60.3 95%CI 17.2,192.2; p < 0.0001). Patients with DQ and DR dnHLAab (OR 115.2: 95%CI 24.8, 509.5; p < 0.0001) and those with donor-specific antibodies (DSAs) (OR 50.8: 95%CI 13.0, 168.7; p < 0.0001) were likely to have dd-cfDNA > 1. A repeated measures linear mixed effect model revealed a significant difference in dd-cfDNA between those with no antibodies or BPAR (p < 0.0001) and patients with BPAR and dnHLAab, with or without DSA. At the end of the follow-up period, eGFR was 72 mL/min/1.73 m2 in those without BPAR or dnHLAab and was significantly different from those with BPAR (eGFR 51 mL/min/1.73 m2 (p < 0.0001). Conclusions: Elevated dd-cfDNA is strongly associated with BPAR, class II dnHLAab and DSAs. Conversely, low values are observed in immunoquiescent states. Dd-cfDNA can be a useful tool for non-invasive clinical decision-making. Graphical


  • Open Access

    Intrapatient Tacrolimus Variability is Associated with Medical Nonadherence among Pediatric Kidney Transplant Recipients

    by Vaka Kristin Sigurjonsdottir, Tara B. Gavcovich, Marissa J. DeFreitas, Claudia Serrano, Esther Rivas, Migdalia Jorge, Wacharee Seeherunvong, Chryso Katsoufis, Wendy Glaberson, Melisa Oliva, et al.

    Background: Long-term survival of kidney allografts is limited by multiple factors, including nonadherence. High intrapatient variability (IPV) in tacrolimus levels (≥30%) is associated with de novo donor-specific antibody (dnDSA) formation, increased risk of rejection and graft loss. Methods: We prospectively analyzed the association between tacrolimus IPV and nonadherence in pediatric kidney transplant recipients. We derived a composite adherence score from 0-3 points based on (1) Basel Assessment of Adherence to Immunosuppressive Medical ScaleÓ; (2) healthcare team score; and (3) intentionally missed laboratory or clinic visits. A score of 1 or more was considered nonadherent. Tacrolimus 12-hour trough levels, patient characteristics and clinical outcomes were collected. Tacrolimus IPV was calculated as the coefficient of variation. Results: The nonadherent group had a significantly higher median tacrolimus IPV (31%) as compared to the adherent cohort (20%) (p < 0.001), with a positive correlation between tacrolimus IPV and composite adherence score (r = 0.44, p < 0.001). Antibody and T-cell mediated rejection, along with dnDSA formation were more prevalent in nonadherent patients and those with a high tacrolimus IPV. Conclusions: Tacrolimus IPV may be a useful biomarker to identify high-risk patients, allowing for early interventions to prevent adverse graft outcomes.

  • Patterns in Tacrolimus Variability and Association with De Novo Donor-Specific Antibody Formation in Pediatric Kidney Transplant Recipients

    by Kim H. Piburn, Vaka K. Sigurjonsdottir, Olafur S. Indridason, Lynn Maestretti, Mary Victoria Patton, Anne McGrath, Runolfur Palsson, Amy Gallo, Abanti Chaudhuri, Paul C. Grimm

    Background and objectives: High tacrolimus intrapatient variability has been associated with inferior graft outcomes in patients with kidney transplants. We studied baseline patterns of tacrolimus intrapatient variability in pediatric patients with kidney transplants and examined these patterns in relation to C1q-binding de novo donor-specific antibodies. Design, setting, participants, & measurements: All tacrolimus levels in participants who underwent kidney-only transplantation at a single pediatric center from 2004 to 2018 (with at least 12-month follow-up, followed until 2019) were analyzed to determine baseline variability. Intrapatient variability was defined using the coefficient of variation (SD/mean ×100%) of all samples in a 6-month moving window. Routine de novo donor-specific antibody measurements were available for a subgroup of patients transplanted in 2010–2018. Cox proportional hazards models using tacrolimus intrapatient variability as a time-varying variable were used to examine the association between intrapatient variability and graft outcomes. The primary outcome of interest was C1q-binding de novo donor-specific antibody formation. Results: Tacrolimus intrapatient variability developed a steady-state baseline of 30% at 10 months post-transplant in 426 patients with a combined 31,125 tacrolimus levels. Included in the outcomes study were 220 patients, of whom 51 developed C1q-binding de novo donor-specific antibodies. De novo donor-specific antibody formers had higher intrapatient variability, with a median of 38% (interquartile range, 28%–48%) compared with 28% (interquartile range, 20%–38%) for nondonor-specific antibody formers (P30%) had higher risk of de novo donor-specific antibody formation (hazard ratio, 5.35; 95% confidence interval, 2.45 to 11.68). Patients in the top quartile of tacrolimus intrapatient variability (coefficient of variation >41%) had the strongest association with C1q-binding de novo donor-specific antibody formation (hazard ratio, 11.81; 95% confidence interval, 4.76 to 29.27). Conclusions: High tacrolimus intrapatient variability was strongly associated with de novo donor-specific antibody formation.


  • Open Access

    Complement-Binding Donor-Specific Anti-HLA Antibodies: Biomarker for Immunologic Risk Stratification in Pediatric Kidney Transplantation Recipients

    by Vaka K. Sigurjonsdottir, Natasha Purington, Abanti Chaudhuri, Bing M. Zhang, Marcelo Fernandez-Vina, Runolfur Palsson, Neeraja Kambham, Vivek Charu, Kim Piburn, Lynn Maestretti, et al.

    Antibody-mediated rejection is a common cause of early kidney allograft loss but the specifics of antibody measurement, therapies and endpoints have not been universally defined. In this retrospective study, we assessed the performance of risk stratification using systematic donor-specific antibody (DSA) monitoring. Included in the study were children who underwent kidney transplantation between January 1, 2010 and March 1, 2018 at Stanford, with at least 12-months follow-up. A total of 233 patients were included with a mean follow-up time of 45 (range, 9–108) months. Median age at transplant was 12.3 years, 46.8% were female, and 76% had a deceased donor transplant. Fifty-two (22%) formed C1q-binding de novo donor-specific antibodies (C1q-dnDSA). After a standardized augmented immunosuppressive protocol was implemented, C1q-dnDSA disappeared in 31 (58.5%). Graft failure occurred in 16 patients at a median of 54 (range, 5–83) months, of whom 14 formed dnDSA. The 14 patients who lost their graft due to rejection, all had persistent C1q-dnDSA. C1q-binding status improved the individual risk assessment, with persistent; C1q binding yielding the strongest independent association of graft failure (hazard ratio, 45.5; 95% confidence interval, 11.7–177.4). C1q-dnDSA is more useful than standard dnDSA as a noninvasive biomarker for identifying patients at the highest risk of graft failure.


  • Low dose rabbit antithymocyte globulin is non-inferior to higher dose in low-risk pediatric kidney transplant recipients

    by Vaka K. Sigurjonsdottir, Lynn Maestretti, Anne McGrath, Waldo Concepcion, Amy Gallo, Urdur Jonsdottir, Paul C. Grimm, Abanti Chaudhuri

    Background Currently, there is no consensus among pediatric kidney transplant centers regarding the use and regimen for immunosuppressive induction therapy. Methods In this single center, retrospective cohort study, pediatric kidney transplant recipients transplanted between 1 May 2013 and 1 May 2018 with rabbit antithymocyte globulin (rATG) induction were included. We stratified patients based on immunological risk, with high risk defined as those with repeat transplant, preformed donor specific antibody, current panel-reactive antibodies > 20%, 0 antigen match and/or African-American heritage. Outcome of interest was the incidence of biopsy proven acute rejection by 1 year. Results A total of 166 patients met inclusion criteria. Age of patients was 12 years (11 mo-21 y), (median, range), 21.5% received a living donor transplant and 50.6% were female. Low-immunologic-risk patients were divided into 2 groups, those who received the lower cumulative rATG dose of ≤ 3.5 mg/kg (n = 52) versus the higher cumulative dose of > 3.5 mg/kg (n = 47). The median total dose in the lower dose group was 3.1 (IQR 0.3) and 4.4 (IQR 0.8) in the higher dose group, P < 0.001. Rejection rate did not differ significantly between the 2 treatment groups (7/52 vs. 6/47). None in the lower dose group developed BK nephropathy versus 3 in the higher dose group. Graft loss due to BK nephropathy occurred in 1 patient in the higher dose group. Graft loss in the whole cohort at 12 months was a rare event (n = 1) with 99.5% graft survival and 100% patient survival. Conclusions Reduced rATG dosing (≤ 3.5 mg/kg) when compared to higher dosing (> 3.5 mg/kg) is safe and effective in low-risk pediatric kidney transplant recipients without increasing risk of rejection. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information


  • Open Access

    Impact of nephrolithiasis on kidney function

    by Vaka K. Sigurjonsdottir, Hrafnhildur L. Runolfsdottir, Olafur S. Indridason, Runolfur Palsson, Vidar O. Edvardsson

    Kidney stone disease has been associated with reduced kidney function and chronic kidney disease (CKD). The objective of the study was to examine kidney function, body mass index (BMI) and the prevalence of cardiovascular disease, hypertension and diabetes in recurrent kidney stone formers. A cross-sectional, case-control study comparing measures of kidney function, BMI and comorbid conditions was conducted in 195 kidney stone patients aged 18 to 70 years with recurrent clinical stone events and 390 age- and gender-matched controls. Wilcoxon-Mann-Whitney, chi-square tests and analysis of covariance were used to compare serum creatinine (SCr) and estimated glomerular filtration rate (eGFR) between the groups. The median age of stone formers was 51 (range, 19–70) years and 108 (55 %) were males. Seventy patients (36 %) had experienced 2–4 clinical stone events, 41 (21 %) 5–10 episodes and 84 (43 %) more than 10. The median SCr was 75 (41–140) μmol/L in the stone formers and 64 (34–168) μmol/L in the control group (p < 0.001). The mean eGFR was 87 ± 20 and 104 ± 22 mL/min/1.73 m2 in the stone formers and controls, respectively (p < 0.001). After adjustment for body size and comorbid conditions, the difference in SCr and eGFR between cases and controls remained highly significant (p < 0.001). The prevalence of CKD was 9.3 % among stone formers compared with 1.3 % in the control group (P < 0.001). Hypertension and diabetes were significantly more prevalent among the cases that also had higher BMI than controls. Recurrent kidney stone formers have a significantly lower level of kidney function and a markedly higher prevalence of CKD than age- and gender-matched control subjects. The observed deleterious effect of kidney stones on kidney function appears to be independent of comorbid conditions.